Crinetics Pharmaceuticals Enhances Employee Incentives
In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units (RSUs) to several new employees. This initiative aligns with the company’s strategy to motivate and reward dedicated professionals entering the organization.
Overview of Inducement Awards
The Compensation Committee granted a total of 78,975 shares worth of non-qualified stock options and 54,475 RSUs to a select group of 20 non-executive employees. These awards were provided under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan, designed specifically for new employees or those rejoining after a bona fide gap in employment. This plan was developed under Nasdaq Listing Rule 5635(c)(4), maintaining compliance while supporting the firm’s growth ambitions.
Details of Stock Options
Each granted stock option has an exercise price of $44.93, mirroring the closing price of the company's stock at the time of the grants. Shares granted through stock options are set to vest over a four-year period, with a quarter vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in equal monthly installments over the subsequent 36 months, contingent on each employee's ongoing employment with Crinetics.
Understanding RSU Vesting
Similarly, the RSUs will also vest across four years in annual installments, beginning a year after the commencement date. Like stock options, their vesting is dependent on the employee’s continued role within Crinetics during the requisite vesting periods. Both awards adhere to the rules outlined in the 2021 Inducement Plan and the respective agreements associated with them.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is dedicated to revolutionizing the treatment for endocrine diseases and related tumors through innovative science that prioritizes patient needs. Their focus lies in the discovery, development, and commercialization of novel therapies. Crinetics specializes in targeting G-protein coupled receptors (GPCRs) using small molecules that are uniquely designed for their pharmacological properties.
Innovative Treatment Solutions
The company is well-known for its lead product, PALSONIFY™ (paltusotine), which is notable for being the first oral, once-daily treatment recognized by the U.S. FDA for adults suffering from acromegaly who either did not respond adequately to surgery or could not undergo it. This product is also examining potential applications for conditions like carcinoid syndrome associated with neuroendocrine tumors, marking a significant potential in the therapeutic landscape.
Diverse Pipeline of Treatments
Crinetics has an extensive pipeline with over ten disclosed programs, including atumelnant, currently in late-stage clinical trials for conditions such as congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. These efforts are integrated with various discovery programs tackling a wide range of endocrine-related issues, including Graves’ disease, polycystic kidney disease, and more.
Company Contact Information
For investor inquiries, Gayathri Diwakar serves as the Head of Investor Relations and can be reached at gdiwakar@crinetics.com or via phone at (858) 345-6340. For media-related queries, Natalie Badillo is the Head of Corporate Communications, available at nbadillo@crinetics.com or (858) 450-6464.
Frequently Asked Questions
What is the purpose of the stock options granted by Crinetics?
The stock options aim to incentivize and reward employees for their contributions, aligning their efforts with the company’s growth plans.
How many shares were granted under the 2021 Inducement Plan?
A total of 78,975 stock options and 54,475 RSUs were granted to 20 new non-executive employees under the plan.
What is the vesting schedule for the granted options?
The stock options vest over four years, with 25% vesting after the first year and the rest vesting in equal monthly installments over the next three years.
What is Crinetics Pharmaceuticals focused on?
Crinetics Pharmaceuticals focuses on developing treatments for endocrine diseases and related tumors, leveraging innovative science to meet patient needs.
Who can be contacted for investor relations at Crinetics?
Gayathri Diwakar, the Head of Investor Relations, is available for questions regarding investor concerns and can be contacted via email or phone.
